The diagnosis and treatment of hepatocellular carcinoma;Diagnose und Therapieoptionen beim hepatozellulären Karzinom

Deutsches Arzteblatt International

Volumn 111, Issue 7, 2014, Pages

  Malek, Nisar P ^a   Schmidt, Sebastian ^b   Huber, Petra ^b   Manns, Michael P ^b   Greten, Tim F ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ARTICLE; CANCER SURGERY; CHILD PUGH SCORE; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; CARCINOMA, HEPATOCELLULAR; INTERNATIONAL COOPERATION; LIVER NEOPLASMS; ONCOLOGY; STANDARDS;

CARCINOMA, HEPATOCELLULAR; HUMANS; INTERNATIONALITY; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 84903371517     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0101     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Esti mates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
4. Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccina - tion in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. The New England Journal of Medicine 1997; 336: 1855-9.
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006; 45: 529-38. (Pubitemid 44307383)
6. Hassan MM, Hwang LY, Hatten CJ, et al.: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13. (Pubitemid 35253437)
7. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
8. Mandayam S, Jamal MM, Morgan TR: Epidemiology of alcoholic liver disease. Seminars in Liver Disease 2004; 24: 217-32. (Pubitemid 39167681)
9. Lu XL, Luo JY, Tao M, et al.: Risk factors for alcoholic liver disease in China. World journal of gastroenterology : WJG 2004; 10: 2423-6. (Pubitemid 39157774)
10. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
11. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver International: Official Journal of the International Association for the Study of the Liver 2010; 30: 750-8.
12. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC: Risk of hepatocellular carcinoma in diabetic patients and risk reduction asso - ciated with anti-diabetic therapy: a population-based cohort study. The American Journal of Gastroenterology 2012; 107: 46-52.
13. El-Serag HB: Hepatocellular carcinoma. The New England Journal of Medicine 2011; 365: 1118-27.
14. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-17. (Pubitemid 37518510)
15. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2004; 130: 417-22.
16. Chen JG, Parkin DM, Chen QG, et al.: Screening for liver cancer: results of a randomised controlled trial in Qidong, China. Journal of Medical Screening 2003; 10: 204-9. (Pubitemid 38091209)
17. Bolondi L: Screening for hepatocellular carcinoma in cirrhosis. Journal of Hepatology 2003; 39: 1076-84. (Pubitemid 37523784)
18. Khalili K, Kim TK, Jang HJ, et al.: Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. Journal of Hepatology 2011; 54: 723-8.
19. Kim JE, Kim SH, Lee SJ, Rhim H: Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR American Journal of Roentgenology 2011; 196: W758-65.
20. Forner A, Vilana R, Ayuso C, et al.: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104. (Pubitemid 351171046)
21. N'Kontchou G, Mahamoudi A, Aout M, et al.: Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-83.
22. Kobayashi M, Hosaka T, Ikeda K, et al.: Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011; 41: 1036-45.
23. Herszenyi L, Farinati F, Cecchetto A, et al.: Fine-needle biopsy in focal liver lesions: the usefulness of a screening programme and the role of cytology and microhistology. Ital J Gastroenterol 1995; 27: 473-8. (Pubitemid 26050951)
24. Caturelli E, Bisceglia M, Fusilli S, Squillante MM, Castelvetere M, Siena DA: Cytological vs microhistological diagnosis of hepatocellular carcinoma: comparative accuracies in the same fine-needle biopsy specimen. Digestive Diseases and Sciences 1996; 41: 2326-31.
25. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999; 19: 329-38.
26. Benson AB, 3rd, Abrams TA, Ben-Josef E, et al.: NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7: 350-91.
27. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS: Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012; 262: 689-700.
28. Gouillat C, Manganas D, Saguier G, Duque-Campos R, Berard P: Resection of hepatocellular carcinoma in cirrhotic patients: longterm results of a prospective study. Journal of the American College of Surgeons 1999; 189: 282-90. (Pubitemid 29408865)
29. Eguchi S, Kanematsu T, Arii S, et al.: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. The British Journal of Surgery 2011; 98: 552-7.
30. Mulier S, Mulier P, Ni Y, et al.: Complications of radiofrequency coagulation of liver tumours. The British Journal of Surgery 2002; 89: 1206-22. (Pubitemid 36002536)
31. Lencioni R, Cioni D, Crocetti L, et al.: Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961-7. (Pubitemid 40250844)
32. Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9. (Pubitemid 34607087)
33. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71. (Pubitemid 34454013)
34. Huppert PE, Lauchart W, Duda SH, et al.: [Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival?]. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2004; 176: 375-85. (Pubitemid 38391371)
35. Marelli L, Stigliano R, Triantos C, et al.: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular and interventional radiology 2007; 30: 6-25. (Pubitemid 44900485)
36. Cheng AL, Kang YK, Chen Z, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 2009; 10: 25-34.
37. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008; 359: 378-90.
38. Lai SW, et al.: Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
39. Khalili K, et al.: Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011 ; 54: 723-8.
40. Kim JE, et al.: Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusionweighted imaging. AJR Am J Roentgenol 2011; 196: 758-65.
41. Baek CK, et al.: Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012; 67: 148-56.
42. Addley HC, et al.: Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clin Radiol 2011; 66: 349-56.
43. Peng ZW, et al.: Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012; 262: 689-700.
44. Kim JH, et al.: Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 2011; 18: 1624-9.
45. Pinter M, et al.: Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-59.
46. Hollebecque A, et al.: Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-201.